Stock Price Reaction
Shares of Indegene climbed nearly 5% on September 25, reaching a level above Rs 621.95, which marked a high not seen in over a year. The rally was triggered by a positive rating action from Motilal Oswal Financial Services, which upgraded the stock to "buy" from its previous "neutral" stance. The brokerage assigned a target price of Rs 708, suggesting a potential upside of approximately 17% from the prevailing market price at the time of the report.
Rationale for Upgrade
Motilal Oswal highlighted that global life sciences and pharmaceutical companies are increasingly outsourcing functions to partners like Indegene to reduce operating costs and accelerate go-to-market strategies. The brokerage noted that internal legal and regulatory review processes often create bottlenecks for pharma firms, delaying campaigns by weeks or months. In contrast, external agencies can streamline these processes, including tagging, referencing, and pre-preview preparations, allowing for faster execution during drug launches.
The report emphasized that while many leading pharmaceutical companies have expanded their global capability centres in India for R&D and IT functions, they have struggled to scale captive centres for commercialisation and omnichannel operations due to talent shortages and rising costs. Indegene is positioned to fill this gap by providing services across R&D, regulatory affairs, and commercialisation.
Operational Metrics and Technology
According to the brokerage, Indegene has retained around 100% of its net revenue over the past five years. During this period, the company digitally profiled and engaged more than three million healthcare professionals, activated over 800 brands, and supported more than 100 product launches.
Indegene has also integrated artificial intelligence into its medical writing platform. This technology, along with AI agents, helps shorten the time between database lock and the submission of regulatory dossiers, enabling medical writers to generate documents more efficiently. Motilal Oswal pointed out that Indegene maintains a strong revenue per employee metric, which exceeds that of its peers in the information technology and healthcare business process outsourcing sectors.
Financial Projections
Looking ahead, Motilal Oswal expects Indegene's revenue to grow at a compounded annual growth rate (CAGR) of 19% between FY27 and FY28. The brokerage projects that earnings before interest and taxes (EBIT) will grow at 29%, while net profit is expected to rise by 27% over the same period. Additionally, the company's EBITDA margin is anticipated to recover to the 19-20% range by the March quarter, driven by operating leverage.